Literature DB >> 17118610

LC and LC-MS study of stress decomposition behaviour of isoniazid and establishment of validated stability-indicating assay method.

Hemant Bhutani1, Saranjit Singh, Sanjay Vir, K K Bhutani, Raj Kumar, Asit K Chakraborti, K C Jindal.   

Abstract

Isoniazid was subjected to different ICH prescribed stress conditions of thermal stress, hydrolysis, oxidation and photolysis. The drug was stable to dry heat (50 and 60 degrees C). It showed extensive decomposition under hydrolytic conditions, while it was only moderately sensitive to oxidation stress. The solid drug turned intense yellow on exposure to light under accelerated conditions of temperature (40 degrees C) and humidity (75% RH). In total, three major degradation products were detected by LC. For establishment of stability-indicating assay, the reaction solutions in which different degradation products were formed were mixed, and the separation was optimized by varying the LC conditions. An acceptable separation was achieved using a C-18 column and a mobile phase comprising of water:acetonitrile (96:4, v/v), with flow rate and detection wavelength being 0.5 ml min(-1) and 254 nm, respectively. The degradation products appeared at relative retention times (RR(T)) of 0.71, 1.34 and 4.22. The validation studies established a linear response of the drug at concentrations between 50 and 1000 microg ml(-1). The mean values (+/-R.S.D.) of slope, intercept and correlation coefficient were 35,199 (+/-0.88), 114,310 (+/-4.70) and 0.9998 (+/-0.01), respectively. The mean R.S.D. values for intra- and inter-day precision were 0.24 and 0.90, respectively. The recovery of the drug ranged between 99.42 and 100.58%, when it was spiked to a mixture of solutions in which sufficient degradation was observed. The specificity was established through peak purity testing using a photodiode array detector. The method worked well on application to marketed formulation of isoniazid, and a fixed-dose combination containing isoniazid and ethambutol HCl. It was even extendable to LC-MS studies, which were carried out to identify the three degradation products. The m/z values of the peaks at RR(T) 0.71 and RR(T) 1.34 matched with isonicotinic acid and isonicotinamide, respectively. The product appearing at RR(T) 4.22 was isolated using preparative LC-MS, and turned out to be a yellow compound that was identified as isonicotinic acid N'-(pyridyl-4-carbonyl)-hydrazide based on mass, FTIR and (1)H/(13)C NMR spectral data. The same was indicated to be responsible for discolouration of isoniazid bulk drug substance and formulations, which is a familiar problem. The mechanism of formation of the said compound is outlined.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17118610     DOI: 10.1016/j.jpba.2006.10.013

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  4 in total

Review 1.  Comparative Stability of Two Anti-hyperpigmentation Agents: Kojic Acid as a Natural Metabolite and Its Di-Palmitate Ester, Under Oxidative Stress; Application to Pharmaceutical Formulation Design.

Authors:  Sahar Tazesh; Elnaz Tamizi; Mohammadreza Siahi Shadbad; Nazli Mostaghimi; Farnaz Monajjemzadeh
Journal:  Adv Pharm Bull       Date:  2021-05-30

2.  (E)-6,6'-(Diazene-1,2-di-yl)bis-(1,10-phenanthrolin-5-ol) tri-chloro-methane disolvate: a superconjugated ligand.

Authors:  Muhib Ahmed; Michael Devereux; Vickie McKee; Malachy McCann; A Denise Rooney
Journal:  Acta Crystallogr E Crystallogr Commun       Date:  2019-07-23

3.  A dual-mode visual detector for toxic hydrazine.

Authors:  Brahmjot Kaur; Rameez Raza; Neil R Branda
Journal:  RSC Adv       Date:  2021-06-28       Impact factor: 4.036

4.  Sodium Hyaluronate Nanocomposite Respirable Microparticles to Tackle Antibiotic Resistance with Potential Application in Treatment of Mycobacterial Pulmonary Infections.

Authors:  Irene Rossi; Francesca Buttini; Fabio Sonvico; Filippo Affaticati; Francesco Martinelli; Giannamaria Annunziato; Diana Machado; Miguel Viveiros; Marco Pieroni; Ruggero Bettini
Journal:  Pharmaceutics       Date:  2019-05-01       Impact factor: 6.321

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.